Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix 2-dose versus 3-dose primary immunization study in healthy females
2011-000757-22Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC) (3 arms), sponsored by GSK. Primary endpoints: Anti-HPV-16/18 seroconversion rates and Anti-HPV-16/18 antibody titres. Started Apr 2011; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on 2011-000757-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000757-22.